Related Experiment Video
Updated: Apr 20, 2026
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Waldenstrom's macroglobulinaemia: to treat or not to treat?
Deepak Sundriyal1, Naveen Kumar2, Sumedha Kotwal1
1Department of Medical Oncology, Dharamshila Hospital and Research Centre, New Delhi, India.
Abstract:
Waldenstrom's macroglobulinaemia (WM) is a rare lymphoproliferative disorder. It is mostly seen in the elderly population with a median age of 65 years at the time of diagnosis. The clinical presentation is variable and the patient may be entirely asymptomatic. The slow progressive nature of the disease allows many patients to survive for more than 5 years. At times it may be difficult for a clinician to determine the timing of therapy. We present an interesting case of WM that highlights the typical course of the disease and timing of its management.
Insights
Waldenstrom's macroglobulinaemia (WM) is a rare slow-growing blood cancer. This case study highlights typical disease progression and optimal timing for initiating treatment in elderly patients.
Area of Science:
- Hematology
- Oncology
- Rare Diseases
Background:
- Waldenstrom's macroglobulinaemia (WM) is a rare lymphoproliferative disorder affecting B-cells.
- It predominantly impacts the elderly, with a median age at diagnosis of 65 years.
- Clinical presentation varies, and patients can be asymptomatic.
Observation:
- The disease typically follows a slow, progressive course.
- Survival often exceeds 5 years, even with delayed treatment.
- Determining the optimal timing for therapy initiation can be challenging for clinicians.
Findings:
- This case illustrates a typical WM disease trajectory.
- It emphasizes the nuances in managing WM, particularly regarding treatment initiation.
- The presentation underscores the variability in patient symptoms and disease progression.
Implications:
- Understanding WM's natural history is crucial for effective patient management.
- This case provides insights into clinical decision-making for therapy timing.
- Further research into optimal treatment strategies for WM is warranted.
